![CLRB - Cellectar Biosciences](https://storage.googleapis.com/iexcloud-hl37opg/api/logos/CLRB.png)
-
Cellectar Biosciences NASDAQ:CLRB Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The company's product pipeline includes one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.
Location: 100 Campus Dr, New Jersey, 07932-1020, US | Website: www.cellectar.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
59.34M
Cash
25.87M
Avg Qtr Burn
-11.29M
Short % of Float
6.20%
Insider Ownership
2.84%
Institutional Own.
34.55%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Iopofosine (CLR 131) Details Multiple myeloma, Cancer, High Refractory Multiple Myeloma | Phase 2 Data readout | |
Iopofosine (CLR 131) Details Cancer, B-cell lymphoma, Lymphoma | Phase 2 Update | |
Iopofosine (CLR 131) Details Cancer, Waldenstrom macroglobulinemia, Lymphoma | Phase 2 Update | |
Iopofosine (CLR 131) Details B-cell lymphoma, B-cell malignancies, Lymphoma, Cancer, Pediatric Sarcomas, High-grade Glioma
| Phase 1b Data readout | |
Iopofosine (CLR 131) + EBRT Details Head and neck cancer, Head and neck squamous cell carcinoma | Phase 1 Update |